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ABSTRACT 
Cancer is not a single disease. It is a group of more than 200 different diseases. Cancer can be generally described as an uncontrolled growth 
and spread of abnormal cells in the body. Cells are basic units of life. All organisms are composed of one or more cells. Nor mally, cells divide to 
produce more cells only when the body needs them. Sometimes cells keep dividing and thus creating more cells even when they are not needed. 
When this happens; a mass of tissue forms. This mass of extra tissue is called a tumor. Tumors are found in all kinds of tissue, and can be benign 
or malignant. 
Keywords: Cancer, Malignant tumor, Antineoplastic agents 
 
 Article Info: Received 12 April 2019;     Review Completed 15 May 2019;     Accepted 20 May 2019;     Available online 22 May 2019 
Cite this article as: 
Kumar P, Singh P, Ramkumar, A Review on recent Anti-Cancer Agents and Drugs containing Pyrazole, Journal of Drug 
Delivery and Therapeutics. 2019; 9(3):753-759     http://dx.doi.org/10.22270/jddt.v9i3.2739                                                   
*Address for Correspondence:  
Praveen Kumar, Faculty of Pharmaceutical Science, Jayoti Vidyapeeth Women’s University Jaipur Rajasthan, India 
 
INTRODUCTION 
How Cancers Develop and Spread: 
Cancer develops only in cells with damaged genes 
(mutations). 
Mutations can be inherited or caused by exposure to: 
– Low-dose radiation 
– Drugs 
– Toxic chemicals  
– Infection with certain viruses can cause mutations. 
– Lifestyle plays a major role in cancer prevention.  
Tumors: 
a) Benign: 
Benign tumors are not cancer. They usually can be removed 
and, in most cases, they do not come back. Most important, 
cells from benign tumors do not spread to other parts of the 
body. Cells from benign tumors stay together and often they 
are surrounded by a containing membrane. Benign tumors 
are not usually a threat to life.1 
b) Malignant 
Malignant tumors are cancer. Cancer cells can invade and 
damage tissues and organs near the tumor. Cancer cells also 
can break away from a malignant tumor and enter the 
lymphatic system or the bloodstream, which is how cancer 
can spread to other parts of the body. The characteristic 
feature of cancer is the cell’s ability to grow rapidly, 
uncontrollably, and independently from the tissue where it 
started. The spread of cancer to other sites or organs in the 
body through the blood stream or lymphatic system is called 
metastasis. 2 
Malignant tumors generally can be classified in two 
categories.  
Carcinomas: These cancers originate in the epithelium. The 
epithelium is the lining cells of an organ. Carcinomas are the 
most common type of cancer. Common sites of carcinomas 
are the skin, mouth, lung, breast, stomach, colon and uterus.  
Sarcomas: Sarcomas are cancers of connective and 
supportive tissue (soft tissues) of all kinds. Sarcomas can be 
found anywhere in the body, and they often form secondary 
growths in the lungs. 3 
 
Figure 1: Process of cancer development 
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Anti-cancer agents: 
Antineoplastic drugs: are most effective against rapidly 
dividing tumor cells. The main goal of Antineoplastic Agents 
is to eliminate the cancer cells without affecting normal 
tissues (the concept of differential sensitivity). In reality, all 
cytotoxic drugs affect normal tissues as well as malignancies 
- aim for a favorable therapeutic index. 
Therapeutic  Index = LD50 / ED50 
A therapeutic index is the lethal dose of a drug for 50% of the 
population (LD50) divided by the minimum effective dose for 
50% of the population (ED50).  
Classification: 4 
A. Drug acting directly on cells (CYTOTOXIC DRUGS): 
1. Alkylating agents: (Nitrogen mustards) 
       Mechlorethamines 
       Cyclophosphamide  
       Ifosfamide   
       Chlorambucil 
       Melphalan 
       Ethylenimine 
       Thio-TEPA 
2. Alkyl sulfonates 
       Busulfan   
       Nitrosoureas 
       Carmustine 
       Lomustine 
       Triazine 
       Dacarbazine 
3. Antimetabolites  
a) Folate antagonist : Methotrexate 
b)  Purine antagonist : 6-mercaptopurine, 6-thioguanine, 
Azathioprine 
c)  Pyrimidine antagonist : 5-Fluorouracil Cytarabine 
(cytosine arabinoside)  
4.  Vinca alkaloids:  Vincristine, Vinblastine 
5.  Taxanes : Paclitaxel, Docetaxel 
6.  Epipodophyllo toxin: Etoposide  
7. Camptothecin analogues: Topotecan, Irinotecan  
8.  Antibiotics: Actinomycin (dactinomycin), 
Doxorubicin, Daunorubicin, Mitoxantrone, Bleomycins, 
Mitomycin C, Mithramycin (plicamycin) 
9.  Miscellaneous: Hydroxyurea, L-Asparaginase, 
Cisplatin  
B.  Drugs altering hormonal milieu  
1. Glucocorticoids: Prednisolone 
2.  Estrogens: Fosfestrol, Ethinylestradiol    
3.  Antiestrogen: Tamoxifen    
4.  Antiandrogen: Flutamide    
5.  5-Alpha reductase inhibitor: Finasteride  
6.  GnRH Analogues: Naferelin, Goserelin    
7.  Progestins: Hydroxyprogesterone acetate 
Chemotherapy: classification based on the mechanism of 
action: 
Antimetabolites: Drugs that interfere with the formation of 
key biomolecules including nucleotides, the building blocks 
of DNA.  
Genotoxic Drugs: Drugs that alkylate or intercalate the DNA 
causing the loss of its function.  
Plant-derived inhibitors of mitosis: These agents prevent 
proper cell division by interfering with the cytoskeletal 
components that enable the cell to divide.  
Plant-derived topoisomerase inhibitors: Topoisomerases  
unwind or religate DNA during replication. 5 
 
 
Cell cycle specificity of Anti-Neoplastic Agents: 
 
Figure 2: Cell cycle specificity of Anti-Neoplastic Agents 
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DEVELOPMENTS LEADING IMPROVEMENT IN ANTI 
CANCER MOIETY 
Sulfur mustard gas-offensive weapon by Germans during 
World War I, destroyed the blood's white cells, leading to 
discovery of drugs used in leukaemia therapy. 
Cl
S
Cl  
6-Mercaptopurine was really the first effective leukemic 
drug for which Hitchings and Elion shared the Nobel Prize in 
1988. 
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Unlike, many cancer drugs available today, Cisplatin 
interferes with the growth of cancer cells by binding to DNA 
and interfering repair mechanism. 6 
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Cisplatin is now THE GOLD STANDARD against which new 
medicines are compared. 
Taxol , generically called Paclitaxel became effective drug for 
treating ovarian, breast and certain forms of lung cancers. 
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Characteristics of Pyrazole: 7 
Structure 
N
HN
 
IUPAC Name 1,2-diazole 
Molecular Formula C3H4N2 
Molecular Weight 68.08 
 
CHEMISTRY OF PYRAZOLE 
Pyrazole is the organic compound with the formula 
C3H3N2H. It is a heterocycle characterized by a 5-membered 
ring of three carbon atoms and two adjacent nitrogen 
centres. Pyrazoles are also the class of compounds that have 
the ring C3N2 with adjacent nitrogen centres. 
 
Table 1: Drugs containing pyrazole moiety 8 
S.No. Name Structure Biological activity 
1. Celecoxib   
O
S
O
N
N
F
F
F
H2N  
NSAIDs 
2. CDPPB   
N
N
HN
O
N
 
 
Antipsychotic effects 
3. Lonazolac   NSAIDs  
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4. Crizotinib   
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Anti-cancer 
5. Tepoxalin   
N
O
N
N
O
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NSAIDs  
6. AS-19   
N
N
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5HT7 receptor agonist 
7. Surinabant   
O
HN N
N
N
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Cannabinoid receptor 
type 1 antagonist 
8. Deracoxib   
O
S
O
N
N
O
F
F
F
H2N  
NSAIDs  
9. Mepiprazole   
N N
Cl
N
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Minor tranquilizer 
10. Tartrazine   Azo dye primarily used 
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as a food coloring. 
11. Rimonabant   
O
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Anorectic antiobesity 
drug 
 
RECENT DEVELOPMENT ON ANTI CANCER AGENTS 
9 
Chemotherapyis the use of anti-cancer of drugs. Anti-cancer 
drugs destroy cancer cells by stopping growth or 
multiplication at some point in their life cycles. Drugs may 
be administered intravenously (into a vein), orally (by 
mouth), by injection into a muscle, topically (applied to the 
skin) or in other ways, depending on the drug and the type 
of cancer. Chemotherapy is often given in cycles of 
alternating treatment and rest periods. 
Recent Drugs: 10 
Belinostat is experimental drug candidate under 
development by TopoTarget for the treatment of 
hematological malignancies and solid tumors. It is a histone 
deacetylase inhibitor.In 2007 preliminary results were 
released from the Phase II clinical trial of intravenous 
belinostat in combination with carboplatin and paclitaxel for 
relapsed ovarian cancer. Final results in late 2009 of a phase 
II trial for T cell lymphoma were encouraging. 
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Idelalisib a drug under investigation for the treatment of 
chronic lymphocytic leukaemia. The substance acts as a 
phosphoinositide 3-kinase inhibitor; more specifically, it 
blocks P110δ, the delta isoform of the enzyme 
phosphoinositide 3-kinase.Approval by the FDA On 25 July 
2014, the FDA granted Idelalisib approval to treat different 
types of leukemia.Idelalisib is a second line drug for patients 
whose chronic lymphocytic leukemia (CLL) has relapsedThe 
FDA is also granted Idelalisib approval to treat patients with 
relapsed follicular B-cell non-Hodgkin lymphoma (FL) and 
relapsed small lymphocytic lymphoma (SLL). 
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Ceritinib is a drug for the treatment of lung cancer. It is an 
ALK inhibitor. It was approved in April 2014 by the Food 
and Drug Administration for the treatment of ALK-positive 
metastatic non-small cell lung cancer (NSCLC) following 
treatment with crizotinib. 11 
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Ibrutinib is an anticancer drug targeting B-cell 
malignancies. It was approved by the US FDA in November 
2013 for the treatment of mantle cell lymphoma and in 
February 2014 for the treatment of chronic lymphocytic 
leukemia. It is an orally-administered, selective and covalent 
inhibitor of the enzyme Bruton's tyrosine kinase (BTK). 
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Trametinib is a cancer drug. It is a MEK inhibitor drug with 
anti-cancer activity. It inhibits MEK1 and MEK2. In May 
2013, trametinib was approved as a single-agent by the Food 
and Drug Administration for the treatment of patients with 
V600E mutated metastatic melanoma. Trametinib had good 
results for metastatic melanoma carrying the BRAF V600E 
mutation in a phase III clinical trial. In this mutation. 12 
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Dabrafenib is a drug for the treatment of cancers associated 
with a mutated version of the gene BRAF. Dabrafenib acts as 
an inhibitor of the associated enzyme B-Raf, which plays a 
role in the regulation of cell growth. The Food and Drug 
Administration approved dabrafenib as a single agent 
treatment for patients with BRAF V600E mutation-positive 
advanced melanoma on May 30, 2013. 
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Imatinib is a tyrosine-kinase inhibitor used in the treatment 
of multiple cancers, most notably Philadelphia chromosome-
positive (Ph+) chronic myelogenous leukemia (CML). 
imatinib works by preventing a tyrosine kinase enzyme, in 
this case BCR-Abl, from phosphorylating subsequent 
proteins and initiating the signalling cascade necessary for 
cancer growth and survival, thus preventing the growth of 
cancer cells and leading to their death by apoptosis. 13 
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Lenalidomide is a derivative of thalidomide introduced in 
2004. It was initially intended as a treatment for multiple 
myeloma, for which thalidomide is an accepted therapeutic 
treatment. Lenalidomide has also shown efficacy in the class 
of hematological disorders known as myelodysplastic 
syndromes (MDS). Lenalidomide has significantly improved 
overall survival in myeloma. 
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Pemetrexed is chemically similar to folic acid and is in the 
class of chemotherapy drugs called folate antimetabolites. It 
works by inhibiting three enzymes used in purine and 
pyrimidine synthesis—thymidylate synthase (TS), 
dihydrofolate reductase (DHFR), and glycinamide 
ribonucleotide formyltransferase (GARFT). By inhibiting the 
formation of precursor purine and pyrimidine nucleotides, 
pemetrexed prevents the formation of DNA and RNA, which 
are required for the growth and survival of both normal cells 
and cancer cells. 14 
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Bortezomib) is the first therapeutic proteasome inhibitor to 
be tested in humans. It is approved in the U.S. for treating 
relapsed multiple myeloma and mantle cell lymphoma. In 
multiple myeloma, complete clinical responses have been 
obtained in patients with otherwise refractory or rapidly 
advancing disease. The boron atom in bortezomib binds the 
catalytic site of the 26S proteasome. 
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Siltuximab is a chimeric (made from human and mouse 
proteins) monoclonal antibody. It binds to interleukin-
6.Siltuximab has been investigated for the treatment of 
metastatic renal cell cancer, prostate cancer, and 
Castleman's disease, among other types of cancer. It has 
undergone a phase I clinical trial in patients With B-cell non-
Hodgkin's lymphoma, multiple myeloma, or Castleman's 
disease. Encouraging results have been reported from a 
phase II trial for relapsed or refractory multiple myeloma. 
On April 23, 2014, Siltuximab was FDA approved under the 
brand name of Sylvant for the treatment of patients with 
multicentric Castleman’s disease (MCD) who do not have 
human immunodeficiency virus (HIV) or human 
herpesvirus-8 (HHV-8). 15 
Ramucirumab is a fully human monoclonal antibody (IgG1) 
developed for the treatment of solid tumors. Ramucirumab 
is being tested in several phase III clinical trials for the 
treatment of metastatic gastric adenocarcinoma, non-small 
cell lung cancer, among other types of cancer. On September 
26, 2013 the manufacturer Eli Lilly announced that its Phase 
III study for ramucirumab failed to hit its primary endpoint 
on progression-free survival among women with metastatic 
breast cancer. On April 21, 2014, the FDA approved 
ramucirumab in treating stomach cancer. 16 
Ofatumumab is a fully human monoclonal antibody (for the 
CD20 protein) which appears to inhibit early-stage B 
lymphocyte activation. It is FDA approved for treating 
chronic lymphocytic leukemia that is refractory to 
fludarabine and alemtuzumab. Its only indication that has 
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received regulatory approval is Chronic lymphocytic 
leukaemia (CLL). It first received FDA approval for this 
indication on the 26th of October 2009, MHRA approval on 
the 19th of April 2010, EMA approval on the 14th of June 
2010 and Health Canada approval on the 13th of August 
2012. 17 
Rituximab was approved by the U.S. Food and Drug 
Administration in 1997 to treat B-cell non-Hodgkin 
lymphomas resistant to other chemotherapy regimens.  
Rituximab, in combination with CHOP chemotherapy, is 
superior to CHOP alone in the treatment of diffuse large B-
cell lymphoma and many other B-cell lymphomas. In 2010 it 
was approved by the European Commission for maintenance 
treatment after initial treatment of follicular lymphoma. 18 
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